INTRODUCTION
Pneumonia is an inflammatory state of the lungs, mainly affecting the alveoli, having diverse causative organisms and mechanisms (1) . Pneumonia is one of the most common infectious diseases, affecting 4 to 6 million people in the United States of America in the form of community acquired pneumonia (CAD), more than a million of those affected requiring hospitalization (2, 3) .
The most common age groups involved are children younger than 5 years of age and elderly aged more than 65 years (4, 5) . Risk factors for acquiring pneumonia include age more than 60 years, alcoholism, cardiac diseases, immunosuppressive therapies, smoking, history of previous pneumonia, mechanical ventilation, body mass index (BMI) less than 18.5, and diabetes (6) (7) (8) (9) (10) . Pneumonia imposes a heavy burden on the health system of nations worldwide with an estimated expenditure of 17 billion dollars in the United States alone (11) ; this is more disturbing, knowing that the disease is almost 5 times The immune system requires different macro-and micro-nutrients to function efficiently (13) , one of the most important being Zinc (Zn). There have been studies suggesting that Zn supplementation might have a beneficial effect in preventing infectious diseases (14) , regulating the immune system, and enhancing the cellular immunity (15) , being an essential factor for the optimal functioning of macrophages and lymphocytes (16) .
Moreover, it has been shown that Zn could function as an anti-oxidant (17) , playing an important role in the course of infectious diseases. It has also been demonstrated that children with low levels of plasma Zn were at a higher risk of acquiring pneumonia (18, 19) . It has also been suggested that supplementation of Zn in the therapeutic regimen of children with pneumonia could improve the results, and boost the chances of leaving the hospital with no long term complications (20) . However, data on the significance of Zn in preventing and treating pneumonia are limited and inconclusive (21) . A study found that supplementation of Zn in children with severe pneumonia did not have any significant effect on the duration of the disease (22) .
Moreover, Zn plasma levels are confounded by several aspects, including geographical factors, race, sex, and socio-economic status (23) (24) (25) , making it harder to generalize the results of these studies to different contexts.
There are also limited studies on the plasma levels of Zn in patients with pneumonia, analyzing the relation between it and the clinical outcome.
The present study sought to further evaluate the effect of plasma levels of Zn on the clinical course of patients with pneumonia, and the relation between the severity of the disease acquired and plasma levels of Zn. patients were included in this study; they were divided into two groups with low (44 patients) and normal (56 patients) plasma zinc levels. The age, sex, and risk factors, such as smoking, occupation, and BMI, were evaluated; the differences between the two groups were not significant. A drug history was obtained from all patients before inclusion in the study. The inclusion criteria were age between 15 and 65 years, and a definite diagnosis of pneumonia on chest radiography, the gold-standard test for the diagnosis of pneumonia (26, 27) . The exclusion criteria were hemodynamic instability, presence of congenital respiratory defects, history of previous autoimmune diseases, pneumonia caused by medication, chemotherapy, hospitalization during the previous year, and use of Zn supplementation during the two months prior to inclusion in the study. All patients were clearly informed about the steps of the study and written informed consent was obtained from all patients; the patients were treated using the most recent guidelines, and after the disease was cured, they were discharged from the infectious disease ward. The study protocol was approved by the Regional Ethics Committee of Tabriz University of Medical Sciences, and was compliant with the tenets of the Declaration of Helsinki. In the present study, an extra 2 cc of blood was obtained from the patients during the tests ordered by the attending specialists in the infectious disease ward; these samples were collected in previously heparinized Eppendoff test tubes and sent to the central laboratory of Tabriz University of Medical Sciences to determine the plasma levels of Zn using a Hitachi 902 biochemistry analyzer and the common kits available.
MATERIALS AND METHODS

During
Plasma levels of Zn more than 60 mg/mL were considered normal (28) and those less than 60 mg/mL were considered low; moreover, the age, sex, severity of pneumonia and the number of days hospitalized, number of days with fever, tachycardia, and tachypnea, and possible mortality were determined for each patient and the means of the aforementioned variables were compared and qualitative data as frequency and percentages (%). For statistical analysis, after determining the distribution of continuous variables using the Klomogorov-Smirnov test, independent sample t-test was used to compare the results between the two groups. Moreover, the collected data were analyzed using descriptive statistical methods, mean difference test for independent groups, and chi-square test or Fisher's exact test. A P-value less than 0.05 was considered statistically significant in all steps.
RESULTS
The mean age was 36. The mean number of days hospitalized and the mean number of days with leukocytosis, tachycardia, tachypnea, and fever in the 100 patients included in the study are summarized in Table 1 . The means of the above-mentioned variables for the two groups and the comparison between them are shown in Table 2 . The differences between the two groups regarding the number of days of hospitalization and the number of days with leukocytosis, tachycardia, tachypnea, and fever were not statistically significant (P>0.05). During the present study, no case of mortality was observed, and all patients were discharged from the infectious disease ward; thus, the groups had no significant differences between them. Regarding the severity of acquired pneumonia as determined by the PSI score, of the total of 100 patients, 28
had severe pneumonia, 26 belonging to the group with low plasma levels of Zn (59%), and the remaining two belonging to the group with normal plasma levels of Zn (3.5%); the difference between the two groups was statistically significant (P=0.001). The data are summarized in Table 1 .
DISCUSSION
During the present cross-sectional study, it was found that there was a significant relation between the Zn plasma levels and the severity of the disease acquired (P=0.001).
However, there was no significant relation between the Zn it was demonstrated that children who used Zn supplements had less morbidity due to respiratory tract infections; the present study did not show any relation between the Zn levels and the morbidity due to pneumonia (30, 31) . 
CONCLUSION
There is a significant relation between the risk of severe pneumonia and plasma levels of Zn, with patients having normal Zn levels being in less danger of severe pneumonia, although there is no significant relation between the plasma levels of Zn in patients with pneumonia and the clinical course of the disease.
